Biochemistry, Pharmacology and Physiology of 2-arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand
Overview
Affiliations
2-Arachidonoylglycerol (2-AG) is a unique molecular species of monoacylglycerol isolated in 1995 from rat brain and canine gut as an endogenous ligand for the cannabinoid receptors. 2-AG is rapidly formed from arachidonic acid-containing phospholipids through increased phospholipid metabolism, such as enhanced inositol phospholipid turnover, in various tissues and cells upon stimulation. 2-AG binds to the cannabinoid receptors (CB1 and CB2) and exhibits a variety of cannabimimetic activities in vitro and in vivo. Notably, anandamide, another endogenous ligand for the cannabinoid receptors, often acts as a partial agonist at these cannabinoid receptors, whereas 2-AG acts as a full agonist in most cases. The results of structure-activity relationship studies suggested that 2-AG rather than anandamide is the true natural ligand for both the CB1 and the CB2 receptors. Evidence is gradually accumulating which shows that 2-AG plays physiologically essential roles in diverse biological systems. For example, several lines of evidence indicate that 2-AG plays an important role as a retrograde messenger molecule in the regulation of synaptic transmission. 2-AG has also been shown to be involved in the regulation of various types of inflammatory reactions and immune responses. In this review, we focused on 2-AG, and summarized information concerning its biosynthesis, metabolism, bioactions and physiological significance, including our latest experimental results.
Effects of and Alkylamides on Respiratory Virus Replication and IL-8 Expression In Vitro.
Puchalski K, Gerstel J, Jimoh A, Shokoohinia Y, Langland J Molecules. 2025; 30(2).
PMID: 39860258 PMC: 11767596. DOI: 10.3390/molecules30020386.
Weiermair T, Svehlikova E, Boulgaropoulos B, Magnes C, Eberl A Sports (Basel). 2024; 12(9).
PMID: 39330709 PMC: 11435531. DOI: 10.3390/sports12090232.
Cannabinoids and triple-negative breast cancer treatment.
Dobovisek L, Borstnar S, Debeljak N, Brezar S Front Immunol. 2024; 15:1386548.
PMID: 39176080 PMC: 11338791. DOI: 10.3389/fimmu.2024.1386548.
Briand-Mesange F, Gennero I, Salles J, Trudel S, Dahan L, Ausseil J Molecules. 2024; 29(15).
PMID: 39125098 PMC: 11314389. DOI: 10.3390/molecules29153694.
Nikas S, Ji L, Liu Y, Georgiadis M, Dopeshwarkar A, Straiker A ACS Med Chem Lett. 2024; 15(6):965-971.
PMID: 38894922 PMC: 11181503. DOI: 10.1021/acsmedchemlett.4c00175.